CHE
Get informed when a big investor buys or sells
+ FollowUndervalued by 57.9% based on the discounted cash flow analysis.
| Market cap | $5.66 Billion |
|---|---|
| Enterprise Value | $5.89 Billion |
| Dividend Yield | $2.40 (0.56%) |
| Earnings per Share | $18.42 |
| Beta | 0.54 |
| Outstanding Shares | 13,675,000 |
| P/E Ratio | 22.45 |
|---|---|
| PEG | -295.27 |
| Price to Sales | 2.31 |
| Price to Book Ratio | 6.88 |
| Enterprise Value to Revenue | 2.32 |
| Enterprise Value to EBIT | 17.07 |
| Enterprise Value to Net Income | 22 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.29 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.9241▼ 146.05% |
|---|---|
| Total Calls | 14,500▲ 271.79% |
| Total Puts | 13,400▲ 44.09% |
Holdings and activity of institutional investors.
| Ownership % | 91.44%▼ 3.76% |
|---|---|
| Total Invested | $4.98B▼ 16.39% |
| Investors Holding | 493▼ 26.00% |
No data
The primary committee for taxation, trade, and entitlement spending, it directly legislates Medicare/Medicaid policy, reimbursement rates, and tax laws, all of which critically impact Chemed's revenue and profitability.
Directly controls and allocates federal spending for all government programs, including Medicare and Medicaid, which are the primary revenue sources for Chemed's home health and hospice services.
Directly regulates health policy and labor laws, impacting staffing costs, workforce regulations, and broader healthcare service delivery, all critical factors for Chemed.